UNSPSC 51151638: Emepronium

This classification denotes a muscarinic antagonist and parasympatholytic with the molecular formula C20H28N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04QQ8SWA4U, chemically known as benzenepropanaminium, n-ethyl-n,n,alpha-trimethyl-gamma-phenyl- but generally known as emepronium, which bears US NIH Compound Identifier 34055. European Medicines Agency schedules Emepronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01875MIG.

World Health Organization schedules emepronium in its Anatomical Therapeutic Chemical (ATC) Classification. EMEPRONIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, EMEPRONIUM remains the US FDA Preferred Term for this commodity. SMILES: [N](C(CC(C1CCCCC1)C1CCCCC1)C)(CC)(C)C.

UNSPSC 51151638 Emepronium, a Commodity code, reflects state and local procurement of pharmaceutical products and related health-support systems for community health and public-sector benefit programs. Recent solicitations show state and local governments purchasing naloxone and drug deactivation systems for emergency response and harm-reduction initiatives, as well as exploring direct-to-manufacturer prescription fulfillment arrangements to improve cost management and efficiency within pharmacy benefit programs. The issuing bodies soliciting under this code include county health departments and state health and human services commissions, indicating activity across both local and statewide jurisdictions focused on pharmaceutical access and public health outcomes.

Geographic activity includes Florida and Texas, with Seminole County procuring naloxone and drug deactivation systems for quarterly delivery to its community health building, and the Texas Health and Human Services Commission conducting market research through an RFI to explore direct-to-manufacturer prescription programs. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the contract includes a two-year initial term with a one-year renewal option, a three-month probationary period, and potential FEMA funding. The Texas HHS RFI (HHS0017013), posted April 3, 2026, is a preliminary information-gathering mechanism seeking vendor capabilities for direct contracting with self-insured employer health plans and state agencies, with no formal evaluation criteria or award values specified at this exploratory stage.